Explore expert perspectives on industry transformation, emerging technologies, and business innovation. Stay ahead with insights from WNS thought leaders.
Read | Jan 11, 2024
AUTHOR(s)
A WNS Perspective
The rising adoption of advanced cancer therapeutics in clinical stages is fueling growth in the cancer immunotherapy market. While Immune Checkpoint Inhibitors (ICIs) have been approved for a wide range of solid tumors, T-cell directed therapies like Chimeric Antigen Receptor-T cells (CAR-Ts) and T-cell redirecting Bispecific T-cell Engagers (BiTEs) are now available for the treatment of hematologic malignancies. Encouraging results for using CAR-Ts and BiTEs in liquid tumors have created interest in expanding these therapies to solid tumors.
While both CAR-Ts and BiTEs present structural similarities, they constitute different therapeutic classes and modes of action. CAR-T cell therapies rely on ex-vivo activation and expansion of T-cells, whereas BiTEs count on the patient’s endogenous T-cells. CAR-Ts are usually administered as a single intravenous infusion, whereas most BiTEs are injected intravenously or subcutaneously once a week, owing to their short half-life. Clinical data gathered so far suggests that BiTEs have a more favorable safety profile in terms of common adverse reactions. At the same time, the efficacy appears to be comparable for both in relapsed / refractory settings.
A looming competition exists between these two modalities, especially in hematological cancers. The success of future market launches will depend on how the treatment paradigm shifts in the years to come. With recent drug approvals and the presence of multiple assets in the late clinical stages, patients may soon have multiple treatment options. The available products will then compete for patient and physician preference at each point in the treatment journey. Hence, it is important to evaluate the risks and benefits of each therapy and optimize the sequence of administration.
BiTEs and CAR-T therapies each offer distinct clinical and commercial advantages. CAR-T therapies provide highly personalized treatment with durable responses, while BiTEs offer off-the-shelf availability, simplified administration and broader scalability. Selecting the optimal modality requires evaluating disease biology, manufacturing complexity, patient accessibility and commercial viability. WNS helps life sciences organizations combine competitive intelligence, market analytics and scientific landscape assessments to build evidence-based oncology portfolio strategies.
The oncology landscape is evolving rapidly with expanding clinical pipelines, regulatory approvals and combination therapy strategies. Pharmaceutical companies need continuous monitoring of clinical evidence, competitor pipelines and physician adoption trends to identify emerging opportunities and commercialization risks. WNS delivers AI-enabled competitive intelligence and market landscape analysis that help organizations prioritize investments, optimize launch strategies and strengthen long-term competitive positioning.
AI enables pharmaceutical companies to analyze clinical trial data, scientific publications, treatment outcomes and competitive intelligence at scale. Advanced analytics supports portfolio prioritization, indication expansion, trial optimization and commercial forecasting across oncology programs. WNS combines AI, scientific analytics and life sciences expertise to help organizations transform complex oncology data into actionable R&D and commercialization insights.
Despite strong clinical potential, both treatment modalities face commercialization challenges including manufacturing complexity, reimbursement considerations, treatment sequencing, safety management, physician adoption and patient accessibility. Successfully navigating these challenges requires integrated clinical intelligence, regulatory monitoring and market access planning. WNS supports pharmaceutical companies through evidence-based market intelligence and commercialization strategies that improve launch readiness and long-term adoption.
WNS combines deep life sciences expertise with AI-powered analytics, competitive intelligence, clinical landscape monitoring and commercialization consulting. From therapy landscape assessments and pipeline benchmarking to market opportunity analysis and launch strategy, WNS helps pharmaceutical organizations make faster, data-driven decisions that strengthen innovation, reduce commercialization risk and maximize the value of next-generation oncology therapies.
Download our paper to know more
Life Sciences; Artificial Intelligence
11 June 2024
Life Sciences
08 December 2023
10 August 2023